Should Canada adopt managed access agreements in Canada for expensive drugs?

"data sharing and transfer liability and intellectual property rights235"

"Canadian Securities Administrators, National Instrument 51-102 — Continuous Disclosure Obligations, s.1.1(1) , https://www.bcsc.bc.ca/-/media/PWS/New-Resources/Securities-Law/Instruments-and-Policies/Policy-5/51102-NI-February-9-2021.pdf (accessed July 15, 2022)."

"Paige A. Thomson & University of Victoria, Negotiated Contracts for Funding Pharmaceuticals: A National Survey of Canadian Public Drug Payers . NHS England Cancer Drugs Fund Team, Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund): A New Deal for Patients, Taxpayers, and Industry , https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf (accessed July 14, 2022). Cancer Care Ontario Ontario Health, Policy: Public Funding of Cancer Drugs within the Context of Clinical Trials , https://www.cancercareontario.ca/sites/ccocancercare/files/assets/CCOClinicalTrialsFundingPolicy.pdf (accessed July 20, 2022). Jan R.R. Lewis, Ian Kerridge & Wendy Lipworth, Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology , 33 JCO 4112 (2015). Thanimalai, Choon & Lee, supra note 148; Sarah Costa et al., Public Perspectives on Disinvestments in Drug Funding: Results from a Canadian Deliberative Public Engagement Event on Cancer Drugs , 19 BMC Public   Health 977 (2019)."